Head of IP - Small Molecule/Chemistry

A comparison of Bristol Myers Squibb and Eli Lilly concludes that Lilly is the better healthcare stock to buy in 2026, even at a premium. Lilly's 2025 revenue rose about 45% to $65.2 billion, with net income near $21 billion. Bristol Myers' revenue slipped 0.2% to $48.2 billion, though it returned to a net income of $7.1 billion after an $8.9 billion loss in 2024. Lilly trades at 33.8 times forward earnings against 8.2 times for Bristol Myers. The article says Bristol Myers is cheap for good reason, citing pricing pressure, patent expiries, and an unpredictable recovery. Lilly's weight-loss drugs Zepbound and Mounjaro are expected to lift 2026 revenue above 30%, to $88.6 billion. Bristol Myers is forecast to grow 3% to $49.9 billion.

Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility. Source link: https://houston365.info/2026/10/09/bristol-myers-squibb-unveils-2-3-billion-investment-in-cutting-edge-houston-pharma-facility/ Bristol Myers Squibb strengthens Houston's life sciences sector with $2.3 billion facility. Bristol Myers Squibb is set to transform Houston's pharmaceutical landscape through a landmark $2.3 billion investment in a cutting-edge manufacturing plant. This initiative, developed in collaboration with the Greater Houston Partnership, aims to elevate the company's production capabilities while cementing Houston's status as a burgeoning center for biopharmaceutical innovation. The project is projected to generate hundreds of skilled jobs and stimulate substantial economic growth within the region. Project overview and strategic importance. The new facility will incorporate the latest manufacturing technologies to optimize efficiency and product quality. With over 1,200 new roles anticipated in scientific research, engineering, and production, the plant will serve as a catalyst for workforce development and community engagement. This expansion aligns with Bristol Myers Squibb's vision to accelerate the delivery of novel therapies and reinforces Houston's growing influence in the life sciences ecosystem. * Innovative manufacturing processes: Adoption of advanced automation and quality control systems. * Employment opportunities: Creation of more than 1,200 specialized jobs across multiple disciplines. * Community collaboration: Strengthening partnerships with local universities and healthcare institutions to foster innovation. | Investment Detail | Information | | Total... | - - Author: Samuel Brown Publish date: 2026-10-09 15:23:00 Copyright for syndicated content belongs to the linked Source. - - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8

Sotyktu gains ground in Psoriatic Arthritis, but rheumatologists remain selective as its role in the treatment algorithm takes shape, according to Spherix Global Insights. New research finds growing prescriber adoption and enthusiasm for TYK2 differentiation, while limited experience, access friction, and questions around joint efficacy temper early launch momentum. Exton, PA, Oct. 06, 2026 (GLOBE NEWSWIRE) - Five months into the U.S. launch of Bristol Myers Squibb's (BMS) Sotyktu (deucravacitinib) for psoriatic arthritis (PsA), rheumatologists are increasingly adding the oral TYK2 inhibitor to their treatment armamentarium. Yet, new research from Spherix Global Insights suggests that broader trial has not yet translated into deep utilization, as physicians continue to refine where Sotyktu fits within an already crowded PsA treatment landscape. Findings from Spherix's latest wave of Launch Dynamix(TM): Sotyktu in Psoriatic Arthritis (US) reveal that 41% of rheumatologists have now prescribed Sotyktu, approximately double the proportion observed shortly after launch. However, depth of use remains limited, with new patient initiations slowing to their lowest level since launch and rheumatologists becoming increasingly selective in the proportion of PsA patients they consider appropriate candidates for the therapy. The pattern suggests that rheumatologists are willing to trial Sotyktu, but are doing so selectively as they gain experience with the product. Importantly, physicians have not written off the drug's longer-term potential. Despite selective use today, rheumatologists continue to anticipate a meaningful role for Sotyktu once fully established, with expectations holding relatively steady throughout the early launch period. A New Oral Option Is Finding Its Niche Sotyktu's novel TYK2 mechanism of action and expected efficacy remains the leading drivers of initiation, with its oral administration and perceived safety profile creating particular appeal for patients who wish to avoid injections or for whom JAK inhibitors may be less desirable. Indeed, nearly two-thirds of rheumatologists believe Sotyktu will expand their overall use of oral therapies in PsA, rather than simply replace another oral agent. This positioning is beginning to translate into a recognizable patient profile. Current Sotyktu use remains concentrated in moderate disease and third-line-or-later treatment, but first-line use has doubled since May, suggesting that some physicians are beginning to experiment with the drug earlier in the treatment journey. The result is an emerging position for Sotyktu somewhere between Otezla and traditionally more potent advanced therapies, an oral option that may appeal both to earlier patients seeking to avoid injectable biologics and to more heavily pretreated patients in need of another mechanism. "I've been using it, like a first-line agent, kind of like a stronger Otezla that has better data." one rheumatologist told Spherix. TYK2 Differentiation Resonates, but Joint Efficacy Remains a Question Rheumatologists appear to recognize meaningful differentiation in Sotyktu's TYK2 mechanism, with its oral profile, perceived safety, and efficacy contributing to an emerging position within the PsA treatment landscape. Early perceptions suggest the therapy may occupy a distinct space among existing oral and advanced treatment options without directly mirroring the profile of any one competitor. At the same time, early clinical experience is introducing some nuance. While physicians report positive experiences among many patients treated to date, questions around joint efficacy relative to established advanced therapies remain, suggesting that greater real-world experience may be important in determining how broadly rheumatologists ultimately use Sotyktu. A Quiet Launch May Be Limiting Momentum Beyond product perceptions, Spherix's findings point to commercial execution as another potential constraint on uptake. More than half of rheumatologists report that they have never interacted with a BMS sales representative for Sotyktu in PsA, and physicians interviewed by Spherix frequently characterized BMS's launch presence as relatively quiet compared with other recent rheumatology launches. Access also remains a friction point. Among recent Sotyktu initiations, 81% required prior authorization, although most were approved on the first attempt. TNF inhibitor failure remains the most common payer requirement. More broadly, rheumatologists' perception of Sotyktu access has become somewhat more restrictive since launch, with nearly one-third now characterizing payers as restricting access. Experience May Be the Next Inflection Point For now, Sotyktu appears to have cleared an important early hurdle: physicians are trying it. The next challenge will be converting that breadth of trial into greater depth of use. Limited familiarity and clinical experience remain the most frequently cited barriers to increased prescribing, while concerns about efficacy, particularly in more severe joint disease, have become more prominent as rheumatologists accumulate experience. Still, Sotyktu's differentiated mechanism, oral administration, and perceived safety advantages give the brand multiple potential paths to growth. With physicians continuing to project meaningful longer-term use, the coming months will help determine whether Sotyktu remains a selectively used alternative or establishes a broader role between Otezla and higher-potency advanced therapies. Launch Dynamix(TM): Sotyktu in Psoriatic Arthritis (US) is an independent Spherix Global Insights service tracking the launch of Sotyktu among U.S. rheumatologists. The August Deep Dive is based on quantitative research with 78 rheumatologists conducted August 5-8, 2026, supplemented by qualitative interviews with six rheumatologists conducted August 24-28. Launch Dynamix provides monthly benchmarking during the first 18 months of commercial availability, augmented by quarterly deep dives examining patient types, brand perceptions, promotional activity, and drivers and barriers to uptake. About Launch Dynamix(TM) Launch Dynamix(TM) is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand. About Spherix Global Insights Spherix Global Insights is a leading independent provider of market intelligence and advisory services for specialty pharmaceutical and biotech markets. By combining physician, patient, and payer perspectives into an integrated view, Spherix helps brand teams, market access stakeholders, and investors understand how a specialty market actually behaves, not how any one stakeholder describes it. The firm operates ten dedicated therapeutic franchises - Dermatology, Gastroenterology, Hematology, Nephrology, Neuroscience, Obesity, Oncology, Ophthalmology, Respiratory and Rheumatology - plus a Market Access team. Each franchise is staffed by hyper-focused experts who track these markets full-time, drawing on independently curated communities of vetted specialists, patients, and payers to deliver quarterly trending, launch tracking, chart audits, and KOL synthesis. Trusted by 19 of the top 20 pharmaceutical and biotech organizations, Spherix has been a go-to resource for more than a decade for leading brands, industry media, financial analysts, and patient advocacy groups. To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com.